血清自身免疫生物标志物对肾移植后IgA肾病复发的预后价值
研究随访96例首次肾移植且原肾为IgA肾病的受者10年,评估移植时或原肾诊断时血清Gd-IgA1及其特异性IgG、IgA自身抗体水平的预后价值。移植时标准化Gd-IgA1特异性IgG自身抗体水平与临床病理复发风险升高相关(相对风险2.68,95%CI 1.26至5.71,P=0.01),多因素分析中为独立危险因素。
要点
- 移植时标准化血清Gd-IgA1特异性IgG自身抗体水平与IgA肾病临床病理复发风险升高相关
- 该指标在多因素分析中为临床病理复发的独立危险因素
- 血清Gd-IgA1水平及Gd-IgA1特异性IgA自身抗体水平未显示与结局相关
核心结论
- 移植后标准化血清IgG抗聚糖自身抗体水平对IgA肾病患者具有预后价值
研究设计与样本
- 连续纳入96例原肾为IgA肾病的首次肾移植受者(79例男性,92例尸供,平均年龄48.1岁),接受以钙调神经磷酸酶抑制剂为基础的免疫抑制治疗,随访10年,观察死亡、移植物失功及临床病理复发(有临床表现且经活检证实)。
- 采用时间依赖Cox回归分析和受试者工作特征曲线评估移植时或原肾IgA肾病诊断时(仅30例)血清Gd-IgA1及Gd-IgA1特异性IgG、IgA自身抗体水平的预后意义。
主要发现
- 随访期间13例死亡,34例移植物失功(其中17例因临床病理复发),34例发生临床病理复发,平均间隔5.8年。
- 与健康对照(n=30)相比,患者在诊断时和移植时血清Gd-IgA1水平显著升高,但该水平与任何结局均无关联。
- 患者在诊断时和移植时标准化(而非总)血清Gd-IgA1特异性IgG自身抗体水平显著升高,移植时该水平与临床病理复发风险升高相关(相对风险2.68;95%CI 1.26至5.71;P=0.01;受试者工作特征曲线下面积0.62;95%CI 0.51至0.74;P=0.05)。
- 多因素分析中标准化Gd-IgA1特异性IgG自身抗体水平仍为临床病理复发的独立危险因素。
- 血清Gd-IgA1特异性IgA自身抗体水平在诊断与移植之间无变化,也未预测结局。
关键数值与推荐
- 移植时标准化血清Gd-IgA1特异性IgG自身抗体水平与临床病理复发相关:相对风险2.68(95%CI 1.26至5.71;P=0.01);曲线下面积0.62(95%CI 0.51至0.74;P=0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A prognostic biomarker for IgA nephropathy (IgAN) recurrence after renal transplant is lacking. We followed 96 consecutive first renal transplant recipients with native kidney IgAN (79 men; 92 deceased donors; mean age =48.1 years) on calcineurin inhibitor-based immunosuppression over 10 years for death, allograft failure, and clinicopathologic recurrence (CPR; clinically evident and biopsy-proven). Using time-dependent Cox regression analysis and receiver operating characteristic curves, we assessed prognostic significance of levels of galactose-deficient IgA1 (Gd-IgA1; autoantigen) and Gd-IgA1-specific IgG and IgA autoantibodies in serum obtained at time of transplant or native-kidney IgAN diagnosis (30 patients only). Overall, 13 patients died, 34 kidneys failed (17 due to CPR), and 34 patients developed CPR after a mean interval of 5.8 years. Compared with healthy controls (n=30), patients had significantly elevated serum Gd-IgA1 levels at diagnosis and transplant, but levels did not associate with any outcome. Patients also had significantly elevated levels of normalized (but not total) serum Gd-IgA1-specific IgG autoantibodies at diagnosis and transplant, and the level at transplant associated with higher risk of CPR (relative risk, 2.68; 95% confidence interval, 1.26 to 5.71; P=0.01; area under the receiver operating characteristic curve, 0.62; 95% confidence interval, 0.51 to 0.74; P=0.05). Normalized Gd-IgA1-specific IgG autoantibody level remained an independent risk factor for CPR in multivariate analysis. Serum Gd-IgA1-specific IgA autoantibody level did not change between diagnosis and transplant or predict outcome. This study emphasizes post-transplant prognostic value of normalized serum IgG antiglycan autoantibody level in patients with IgAN.
引用
- Berthoux F, Suzuki H, Mohey H, et al. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation. J Am Soc Nephrol. 2017. PMID: 28255003. doi:10.1681/ASN.2016060670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。